PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of cmrPermissionsJournals.ASM.orgJournalCMR ArticleJournal InfoAuthorsReviewers
 
Clin Microbiol Rev. 1988 April; 1(2): 187–217.
PMCID: PMC358042

Overview of medically important antifungal azole derivatives.

Abstract

Fungal infections are a major burden to the health and welfare of modern humans. They range from simply cosmetic, non-life-threatening skin infections to severe, systemic infections that may lead to significant debilitation or death. The selection of chemotherapeutic agents useful for the treatment of fungal infections is small. In this overview, a major chemical group with antifungal activity, the azole derivatives, is examined. Included are historical and state of the art information on the in vitro activity, experimental in vivo activity, mode of action, pharmacokinetics, clinical studies, and uses and adverse reactions of imidazoles currently marketed (clotrimazole, miconazole, econazole, ketoconazole, bifonazole, butoconazole, croconazole, fenticonazole, isoconazole, oxiconazole, sulconazole, and tioconazole) and under development (aliconazole and omoconazole), as well as triazoles currently marketed (terconazole) and under development (fluconazole, itraconazole, vibunazole, alteconazole, and ICI 195,739).

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (6.8M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Abruzzo GK, Giltinan DM, Capizzi TP, Fromtling RA. Influence of six antifungal agents on the chemiluminescence response of mouse spleen cells. Antimicrob Agents Chemother. 1986 Apr;29(4):602–607. [PMC free article] [PubMed]
  • Ackerbauer H, Meingassner JG, Mieth H. Experimentelle renale Infektionen der Maus mit Aspergillus fumigatus: Ein chemotherapeutisches Modell einer Organmykose. Mykosen. 1985 May;28(5):244–250. [PubMed]
  • Alford RH, Cartwright BB. Comparison of ketoconazole and amphotericin B in interference with thymidine uptake by and blastogenesis of lymphocytes stimulated with Histoplasma capsulatum antigens. Antimicrob Agents Chemother. 1983 Oct;24(4):575–578. [PMC free article] [PubMed]
  • Anséhn S, Nilsson L. Direct membrane-damaging effect of ketoconazole and tioconazole on Candida albicans demonstrated by bioluminescent assay of ATP. Antimicrob Agents Chemother. 1984 Jul;26(1):22–25. [PMC free article] [PubMed]
  • Artner J, Fuchs G. Open studies of the efficacy, tolerance, systemic absorption and vaginal persistence following a single application of tioconazole ointment in the treatment of patients with vaginal candidiasis. Gynakol Rundsch. 1983;23 (Suppl 1):12–19. [PubMed]
  • Athow-Frost TA, Freeman K, Mann TA, Marks R, Vollum D, Warin AP. Clinical evaluation of fenticonazole cream in cutaneous fungal infections: a comparison with miconazole cream. Curr Med Res Opin. 1986;10(2):107–116. [PubMed]
  • Balbi C, D'Ajello M, Balbi GC. Treatment with ketoconazole in diabetic patients with vaginal candidiasis. Drugs Exp Clin Res. 1986;12(5):413–414. [PubMed]
  • Barug D, de Groot C. Microscopic studies of Candida albicans and Torulopsis glabrata after in vitro treatment with bifonazole. Freeze fracture electron microscopy. Arzneimittelforschung. 1983;33(4):538–545. [PubMed]
  • Bastide M, Jouvert S, Bastide JM. A comparison of the effects of several antifungal imidazole derivatives and polyenes on Candida albicans: an ultrastructural study by scanning electron microscopy. Can J Microbiol. 1982 Oct;28(10):1119–1126. [PubMed]
  • Baxter JG, Brass C, Schentag JJ, Slaughter RL. Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs. J Pharm Sci. 1986 May;75(5):443–447. [PubMed]
  • Beggs WH. Comparison of miconazole- and ketoconazole-induced release of K+ from Candida species. J Antimicrob Chemother. 1983 Apr;11(4):381–383. [PubMed]
  • Beggs WH. Fungicidal activity of tioconazole in relation to growth phase of Candida albicans and Candida parapsilosis. Antimicrob Agents Chemother. 1984 Nov;26(5):699–701. [PMC free article] [PubMed]
  • Beggs WH. Influence of growth phase on the susceptibility of Candida albicans to butoconazole, oxiconazole, and sulconazole. J Antimicrob Chemother. 1985 Sep;16(3):397–399. [PubMed]
  • Beggs WH. Rapid fungicidal action of tioconazole and miconazole. Mycopathologia. 1987 Mar;97(3):187–188. [PubMed]
  • Beggs WH, Hughes CE. Irrelevance of growth phase with respect to the Bay n 7133 and ICI 153,066 susceptibilities of Candida albicans. Diagn Microbiol Infect Dis. 1986 Jan;4(1):83–86. [PubMed]
  • Beggs WH, Hughes CE. Exploitation of the direct cell damaging action of antifungal azoles. Diagn Microbiol Infect Dis. 1987 Jan;6(1):1–3. [PubMed]
  • Benijts G, Vignalli M, Kreysing W, Stettendorf S. Three-day therapy of vaginal candidiasis with clotrimazole vaginal tablets and econazole ovules: a multicentre comparative study. Curr Med Res Opin. 1980;7(1):55–61. [PubMed]
  • Bennett JE, Remington JS. Miconazole in cryptococcosis and systemic candidiasis: a word of caution. Ann Intern Med. 1981 May;94(5):708–709. [PubMed]
  • Berg D, Regel E, Harenberg HE, Plempel M. Bifonazole and clotrimazole. Their mode of action and the possible reason for the fungicidal behaviour of bifonazole. Arzneimittelforschung. 1984;34(2):139–146. [PubMed]
  • Bergan T, Vangdal M. In vitro activity of antifungal agents against yeast species. Chemotherapy. 1983;29(2):104–110. [PubMed]
  • Best TR, Jenkins JK, Murphy FY, Nicks SA, Bussell KL, Vesely DL. Persistent adrenal insufficiency secondary to low-dose ketoconazole therapy. Am J Med. 1987 Mar 23;82(3 Spec No):676–680. [PubMed]
  • Cornelis G, Laroche Y, Balligand G, Sory MP, Wauters G. Yersinia enterocolitica, a primary model for bacterial invasiveness. Rev Infect Dis. 1987 Jan-Feb;9(1):64–87. [PubMed]
  • Botter AA. Topical treatment of nail and skin infections with miconazole, a new broad-spectrum antimycotic. Mykosen. 1971 Apr 1;14(4):187–191. [PubMed]
  • Bradbeer CS, Mayhew SR, Barlow D. Butoconazole and miconazole in treating vaginal candidiasis. Genitourin Med. 1985 Aug;61(4):270–272. [PMC free article] [PubMed]
  • Brass C, Galgiani JN, Blaschke TF, Defelice R, O'Reilly RA, Stevens DA. Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother. 1982 Jan;21(1):151–158. [PMC free article] [PubMed]
  • Brewster E, Preti PM, Ruffmann R, Studd J. Effect of fenticonazole in vaginal candidiasis: a double-blind clinical trial versus clotrimazole. J Int Med Res. 1986;14(6):306–310. [PubMed]
  • Brown D, Jr, Henzl MR, LePage ME, Tsao LL, Izu AE, Walker KA, Adamson GD, Droegmuller W. Butoconazole vaginal cream in the treatment of vulvovaginal candidiasis. Comparison with miconazole nitrate and placebo. J Reprod Med. 1986 Nov;31(11):1045–1048. [PubMed]
  • Brugmans JP, Thienpont DC, van Wijngaarden I, Vanparijs OF, Schuermans VL, Lauwers HL. Mebendazole in enterobiasis. Radiochemical and pilot clinical study in 1,278 subjects. JAMA. 1971 Jul 19;217(3):313–316. [PubMed]
  • Bullock WE, Deepe GS., Jr Medical mycology in crisis. J Lab Clin Med. 1983 Nov;102(5):685–693. [PubMed]
  • Burgess MA, Bodey GP. Clotrimazole (Bay b 5097): in vitro and clinical pharmacological studies. Antimicrob Agents Chemother. 1972 Dec;2(6):423–426. [PMC free article] [PubMed]
  • Cacciaglia GB, Tenczar AJ, Kanat IO. Pharmacologic review: a review of the literature of ketoconazole therapy in the treatment of tinea pedis and onychomycosis. J Foot Surg. 1984 Sep-Oct;23(5):420–423. [PubMed]
  • Cartwright RY. Clotrimazole in the treatment of acute and "resistant' vaginal candidiasis. Postgrad Med J. 1974 Jul;50 (Suppl 1):90–92. [PubMed]
  • Cauwenbergh G. Prophylaxis of mycotic infections in immunocompromised patients: a review of 27 reports and publications. Drugs Exp Clin Res. 1986;12(5):419–427. [PubMed]
  • Chandler FW. Pathology of the mycoses in patients with the acquired immunodeficiency syndrome (AIDS). Curr Top Med Mycol. 1985;1:1–23. [PubMed]
  • Clayton YM, Connor BL. Comparison of clotrimazole cream, Whitfield's ointment and Nystatin ointment for the topical treatment of ringworm infections, pityriasis versicolor, erythrasma and candidiasis. Br J Dermatol. 1973 Sep;89(3):297–303. [PubMed]
  • Clissold SP, Heel RC. Tioconazole. A review of its antimicrobial activity and therapeutic use in superficial mycoses. Drugs. 1986 Jan;31(1):29–51. [PubMed]
  • Cope JE. Mode of action of miconazole on Candida albicans: effect on growth, viability and K+ release. J Gen Microbiol. 1980 Jul;119(1):245–251. [PubMed]
  • Corrado ML, Kramer M, Cummings M, Eng RH. Susceptibility of dermatiaceous fungi to amphotericin B, miconazole, ketoconazole, flucytosine and rifampin alone and in combination. Sabouraudia. 1982 Jun;20(2):109–113. [PubMed]
  • Costa AL. "In vitro" antimycotic activity of fenticonazole (Rec 15/1476). Mykosen. 1982 Jan;25(1):47–52. [PubMed]
  • Costa AL, Valenti A, Veronese M. Study of the morphofunctional alterations produced by fenticonazole on strains of Candida albicans, using the scanning electron microscope (S.E.M). Mykosen. 1984 Jan;27(1):29–35. [PubMed]
  • Cusumano V, Costa AL, Veronese M. Evaluation of the antifungal activity of fenticonazole on strains of Candida albicans on cellular lines. Mykosen. 1985 May;28(5):238–243. [PubMed]
  • Daneshmend TK. Systemic absorption of miconazole from the vagina. J Antimicrob Chemother. 1986 Oct;18(4):507–511. [PubMed]
  • Daneshmend TK, Warnock DW, Ene MD, Johnson EM, Potten MR, Richardson MD, Williamson PJ. Influence of food on the pharmacokinetics of ketoconazole. Antimicrob Agents Chemother. 1984 Jan;25(1):1–3. [PMC free article] [PubMed]
  • D'Arcy PF, Scott EM. Antifungal agents. Prog Drug Res. 1978;22:93–147. [PubMed]
  • DeFelice R, Johnson DG, Galgiani JN. Gynecomastia with ketoconazole. Antimicrob Agents Chemother. 1981 Jun;19(6):1073–1074. [PMC free article] [PubMed]
  • Del Palacio-Hernanz A, Sanz-Sanz F, Rodriquez-Noriega A. Double-blind investigation of R-42470 (terconazole cream 0.4%) and clotrimazole (cream 1%) for the topical treatment of mycotic vaginitis. Chemioterapia. 1984 Jun;3(3):192–195. [PubMed]
  • Feldman RM, Singer C. Noncardiogenic pulmonary edema and pulmonary fibrosis in falciparum malaria. Rev Infect Dis. 1987 Jan-Feb;9(1):134–139. [PubMed]
  • De Nollin S, Van Belle H, Goossens F, Thone F, Borgers M. Cytochemical and biochemical studies of yeasts after in vitro exposure to miconazole. Antimicrob Agents Chemother. 1977 Mar;11(3):500–513. [PMC free article] [PubMed]
  • Dieperink H, Møller J. Ketoconazole and cyclosporin. Lancet. 1982 Nov 27;2(8309):1217–1217. [PubMed]
  • Dismukes WE, Stamm AM, Graybill JR, Craven PC, Stevens DA, Stiller RL, Sarosi GA, Medoff G, Gregg CR, Gallis HA, et al. Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study. Ann Intern Med. 1983 Jan;98(1):13–20. [PubMed]
  • Dixon DM, Polak A. In vitro and in vivo drug studies with three agents of central nervous system phaeohyphomycosis. Chemotherapy. 1987;33(2):129–140. [PubMed]
  • Dixon D, Shadomy S, Shadomy HJ, Espinel-Ingroff A, Kerkering TM. Comparison of the in vitro antifungal activities of miconazole and a new imidazole, R41,400. J Infect Dis. 1978 Aug;138(2):245–248. [PubMed]
  • Droegemueller W, Adamson DG, Brown D, Cibley L, Fleury F, LePage ME, Henzl MR. Three-day treatment with butoconazole nitrate for vulvovaginal candidiasis. Obstet Gynecol. 1984 Oct;64(4):530–534. [PubMed]
  • Duarte PA, Chow CC, Simmons F, Ruskin J. Fatal hepatitis associated with ketoconazole therapy. Arch Intern Med. 1984 May;144(5):1069–1070. [PubMed]
  • Dupont B, Drouhet E. Cryptococcal meningitis and fluconazole. Ann Intern Med. 1987 May;106(5):778–778. [PubMed]
  • Espinel-Ingroff A, Shadomy S, Fisher JF. Bioassay for miconazole. Antimicrob Agents Chemother. 1977 Feb;11(2):365–368. [PMC free article] [PubMed]
  • Espinel-Ingroff A, Shadomy S, Gebhart RJ. In vitro studies with R 51,211 (itraconazole). Antimicrob Agents Chemother. 1984 Jul;26(1):5–9. [PMC free article] [PubMed]
  • Fainstein V, Bodey GP, Elting L, Maksymiuk A, Keating M, McCredie KB. Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients. Antimicrob Agents Chemother. 1987 Jan;31(1):11–15. [PMC free article] [PubMed]
  • Farkas B, Simon N. Ergebnisse einer Vergleichsstudie mit einem oral und einem lokal zu applizierenden Antimykotikum bei Vaginalmykosen. Mykosen. 1984 Nov;27(11):554–561. [PubMed]
  • Feldman D. Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocr Rev. 1986 Nov;7(4):409–420. [PubMed]
  • Finzi A, Fioroni A, Monici Preti P, Mounari M. A double blind evaluation of fenticonazole cream 2% and clotrimazole cream 1% in dermatomycoses. Mykosen. 1986 Jan;29(1):41–44. [PubMed]
  • Fraser DW, Ward JI, Ajello L, Plikaytis BD. Aspergillosis and other systemic mycoses. The growing problem. JAMA. 1979 Oct 12;242(15):1631–1635. [PubMed]
  • Fromtling RA, Abruzzo GK, Bulmer GS. Cryptococcus neoformans: comparisons of in vitro antifungal susceptibilities of serotypes AD and BC. Mycopathologia. 1986 Apr;94(1):27–30. [PubMed]
  • Fromtling RA, Yu HP, Shadomy S. In-vitro inhibitory activities of 2 new orally absorbable imidazole derivatives: BAY n 7133 and BAY 1 9139. Sabouraudia. 1983 Sep;21(3):179–184. [PubMed]
  • Fromtling RA, Yu HP, Shadomy S. In vitro antifungal activities of Bay n 7133 and Bay L 9139, two new orally absorbed antifungal imidazole derivatives, against pathogenic yeasts. Mycopathologia. 1984 Apr 30;86(1):45–50. [PubMed]
  • Galgiani JN. Ketoconazole in the treatment of coccidioidomycosis. Drugs. 1983 Oct;26(4):355–363. [PubMed]
  • Feldman RM, Singer C. Noncardiogenic pulmonary edema and pulmonary fibrosis in falciparum malaria. Rev Infect Dis. 1987 Jan-Feb;9(1):134–139. [PubMed]
  • Gan VN, Petruska M, Ginsburg CM. Epidemiology and treatment of tinea capitis: ketoconazole vs. griseofulvin. Pediatr Infect Dis J. 1987 Jan;6(1):46–49. [PubMed]
  • Gebhart RJ, Espinel-Ingroff A, Shadomy S. In vitro susceptibility studies with oxiconazole (Ro 13-8996). Chemotherapy. 1984;30(4):244–247. [PubMed]
  • Georgopapadakou NH, Dix BA, Smith SA, Freudenberger J, Funke PT. Effect of antifungal agents on lipid biosynthesis and membrane integrity in Candida albicans. Antimicrob Agents Chemother. 1987 Jan;31(1):46–51. [PMC free article] [PubMed]
  • Gip L. Comparison of oxiconazole (Ro 13-8996) and econazole in dermatomycoses. Mykosen. 1984 Jun;27(6):295–302. [PubMed]
  • Gip L, Forsström S. A double-blind parallel study of sulconazole nitrate 1% cream compared with miconazole nitrate 2% cream in dermatophytoses. Mykosen. 1983 May;26(5):231–241. [PubMed]
  • Godefroi EF, Heeres J, Van Cutsem J, Janssen PA. The preparation and antimycotic properties of derivatives of 1-phenethylimidazole. J Med Chem. 1969 Sep;12(5):784–791. [PubMed]
  • Gouveia DC, Jones da Silva C. Oxiconazole in the treatment of vaginal candidiasis: single dose versus 3-day treatment with econazole. Pharmatherapeutica. 1984;3(10):682–685. [PubMed]
  • Graybill JR, Ahrens J. Itraconazole treatment of murine aspergillosis. Sabouraudia. 1985 Jun;23(3):219–223. [PubMed]
  • Graybill JR, Kaster SR, Drutz DJ. Comparative activities of Bay n7133, ICI 153,066, and ketoconazole in murine cryptococcosis. Antimicrob Agents Chemother. 1983 Dec;24(6):829–834. [PMC free article] [PubMed]
  • Graybill JR, Kaster SR, Drutz DJ. Treatment of experimental murine aspergillosis with BAY n7133. J Infect Dis. 1983 Nov;148(5):898–906. [PubMed]
  • Graybill JR, Levine HB. Successful treatment of cryptococcal meningitis with intraventricular miconazole. Arch Intern Med. 1978 May;138(5):814–816. [PubMed]
  • Graybill JR, Sun SH, Ahrens J. Treatment of murine coccidioidal meningitis with fluconazole (UK 49,858). J Med Vet Mycol. 1986 Apr;24(2):113–119. [PubMed]
  • Green CA, Farr PM, Shuster S. Treatment of seborrhoeic dermatitis with ketoconazole: II. Response of seborrhoeic dermatitis of the face, scalp and trunk to topical ketoconazole. Br J Dermatol. 1987 Feb;116(2):217–221. [PubMed]
  • Greene NB, Baughman RP, Kim CK, Roselle GA. Failure of ketoconazole in an immunosuppressed patient with pulmonary blastomycosis. Chest. 1985 Oct;88(4):640–641. [PubMed]
  • Grigoriu D, Grigoriu A. Double-blind comparison of the efficacy, toleration and safety of tioconazole base 1% and econazole nitrate 1% creams in the treatment of patients with fungal infections of the skin or erythrasma. Dermatologica. 1983;166 (Suppl 1):8–13. [PubMed]
  • Guaschino S, Michelone G, Stola E, Lombardi G, Spinillo A, Viale P. Mycotic vaginitis in pregnancy: a double evaluation of the susceptibility to the main antimycotic drugs of isolated species. Biol Res Pregnancy Perinatol. 1986;7(1):20–22. [PubMed]
  • Hansen RM, Reinerio N, Sohnle PG, Abrams RA, Ritch PS, Libnoch JA, Anderson T. Ketoconazole in the prevention of candidiasis in patients with cancer. A prospective, randomized, controlled, double-blind study. Arch Intern Med. 1987 Apr;147(4):710–712. [PubMed]
  • Hay RJ, Mackie RM, Clayton YM. Tioconazole nail solution--an open study of its efficacy in onychomycosis. Clin Exp Dermatol. 1985 Mar;10(2):111–115. [PubMed]
  • Heel RC, Brogden RN, Carmine A, Morley PA, Speight TM, Avery GS. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs. 1982 Jan-Feb;23(1-2):1–36. [PubMed]
  • Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS. Miconazole: a preliminary review of its therapeutic efficacy in systemic fungal infections. Drugs. 1980 Jan;19(1):7–30. [PubMed]
  • Heeres J, Backx LJ, Mostmans JH, Van Cutsem J. Antimycotic imidazoles. part 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent. J Med Chem. 1979 Aug;22(8):1003–1005. [PubMed]
  • Heeres J, Backx LJ, Van Cutsem J. Antimycotic azoles. 7. Synthesis and antifungal properties of a series of novel triazol-3-ones. J Med Chem. 1984 Jul;27(7):894–900. [PubMed]
  • Heeres J, Hendrickx R, Van Cutsem J. Antimycotic azoles. 6. Synthesis and antifungal properties of terconazole, a novel triazole ketal. J Med Chem. 1983 Apr;26(4):611–613. [PubMed]
  • Henderson JT, Neilson W, Wilson AB, Jevons S. Tioconazole in the treatment of vaginal candidiasis. An international clinical research program. Gynakol Rundsch. 1983;23 (Suppl 1):42–60. [PubMed]
  • HERRLING S, SOUS H, KRUEPE W, OSTERLOH G, MUECKTER H. [Experimental studies on a new combination effective against fungi]. Arzneimittelforschung. 1959 Aug;9:489–494. [PubMed]
  • Hoeprich PD, Goldstein E. Miconazole therapy for coccidioidomycosis. JAMA. 1974 Nov 25;230(8):1153–1157. [PubMed]
  • Hoeprich PD, Merry JM. In vitro activities of two new antifungal azoles. Antimicrob Agents Chemother. 1984 Mar;25(3):339–341. [PMC free article] [PubMed]
  • Hoeprich PD, Merry JM. Activity of BAY n 7133 and BAY 1 9139 in vitro and in experimental murine coccidioidomycosis. Eur J Clin Microbiol. 1985 Aug;4(4):400–403. [PubMed]
  • Hoeprich PD, Merry JM. Influence of culture medium on susceptibility testing with BAY n 7133 and ketoconazole. J Clin Microbiol. 1986 Aug;24(2):269–271. [PMC free article] [PubMed]
  • Höffken G, Lode H, Kessler HJ. Einfluss von Doxycyclin und Isoconazolnitrat auf die intestinale Pilzflora des Menschen. Arzneimittelforschung. 1983;33(2):273–276. [PubMed]
  • Holt RJ, Newman RL. Laboratory assessment of the antimycotic drug clotrimazole. J Clin Pathol. 1972 Dec;25(12):1089–1097. [PMC free article] [PubMed]
  • Houang ET, Lawrence AG. Systemic absorption and persistence of tioconazole in vaginal fluid after insertion of a single 300-mg tioconazole ovule. Antimicrob Agents Chemother. 1985 Jun;27(6):964–965. [PMC free article] [PubMed]
  • Huang YC, Colaizzi JL, Bierman RH, Woestenborghs R, Heykants J. Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Antimicrob Agents Chemother. 1986 Aug;30(2):206–210. [PMC free article] [PubMed]
  • Hughes CE, Beggs WH. Action of fluconazole (UK-49,858) in relation to other systemic antifungal azoles. J Antimicrob Chemother. 1987 Feb;19(2):171–174. [PubMed]
  • Hume AL, Kerkering TM. Ketoconazole. Drug Intell Clin Pharm. 1983 Mar;17(3):169–174. [PubMed]
  • Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother. 1985 Nov;28(5):648–653. [PMC free article] [PubMed]
  • Hussain Qadri SM, Flournoy DJ, Qadri SG, Ramirez EG. Susceptibility of clinical isolates of yeasts to anti-fungal agents. Mycopathologia. 1986 Sep;95(3):183–187. [PubMed]
  • Ishibashi Y, Matsumoto Y. Intravenous miconazole therapy for experimental keratomycosis in rabbits. Sabouraudia. 1985 Feb;23(1):55–61. [PubMed]
  • Jacobson JB, Hajman AJ, Wiese J, Gandrup P, Forsström S. A new vaginal antifungal agent--butoconazole nitrate. Acta Obstet Gynecol Scand. 1985;64(3):241–244. [PubMed]
  • Janssen PA, Symoens JE. Hepatic reactions during ketoconazole treatment. Am J Med. 1983 Jan 24;74(1B):80–85. [PubMed]
  • Jevons S, Gymer GE, Brammer KW, Cox DA, Leeming MR. Antifungal activity of tioconazole (UK-20,349), a new imidazole derivative. Antimicrob Agents Chemother. 1979 Apr;15(4):597–602. [PMC free article] [PubMed]
  • Jordan WM, Bodey GP, Rodriguez V, Ketchel SJ, Henney J. Miconazole therapy for treatment of fungal infections in cancer patients. Antimicrob Agents Chemother. 1979 Dec;16(6):792–797. [PMC free article] [PubMed]
  • Kashin P, Phyfferoen MC, Gibbs DL. A comparative study of once versus twice daily treatment of superficial dermatophyte and yeast infections with tioconazole (1%) cream. J Int Med Res. 1985;13(2):88–95. [PubMed]
  • Katz ME, Cassileth PA. Disseminated candidiasis in a patient with acute leukemia. Successful treatment with miconazole. JAMA. 1977 Mar 14;237(11):1124–1125. [PubMed]
  • Kessler HJ. Mikrobiologische Untersuchungen mit Isoconazolnitrat, einem Breitspektrum-Antimykotikum aus der Gruppe der Imidazol-Derivate. Arzneimittelforschung. 1979;29(9):1344–1351. [PubMed]
  • Kessler HJ, Haude D, Schöbel C. Tierexperimentelle Prüfung des neuen Breitspektrum-Antimykotikums Isoconazolnitrat. Arzneimittelforschung. 1979;29(9):1352–1357. [PubMed]
  • Kirkpatrick CH, Alling DW. Treatment of chronic oral candidiasis with clotrimazole troches. A controlled clinical trial. N Engl J Med. 1978 Nov 30;299(22):1201–1203. [PubMed]
  • Kjaeldgaard A. Comparison of terconazole and clotrimazole vaginal tablets in the treatment of vulvovaginal candidosis. Pharmatherapeutica. 1986;4(8):525–531. [PubMed]
  • Kobayashi GS, Travis S, Medoff G. Comparison of the in vitro and in vivo activity of the bis-triazole derivative UK 49,858 with that of amphotericin B against Histoplasma capsulatum. Antimicrob Agents Chemother. 1986 Apr;29(4):660–662. [PMC free article] [PubMed]
  • Kokoschka EM, Niebauer G, Mounari M, Monici Preti P. Treatment of dermatomycoses with topical fenticonazole and econazole. Mykosen. 1986 Jan;29(1):45–50. [PubMed]
  • Kowal J. The effect of ketoconazole on steroidogenesis in cultured mouse adrenal cortex tumor cells. Endocrinology. 1983 Apr;112(4):1541–1543. [PubMed]
  • Kraemer FB, Pont A. Inhibition of cholesterol synthesis by ketoconazole. Am J Med. 1986 Apr;80(4):616–622. [PubMed]
  • Lake-Bakaar G, Scheuer PJ, Sherlock S. Hepatic reactions associated with ketoconazole in the United Kingdom. Br Med J (Clin Res Ed) 1987 Feb 14;294(6569):419–422. [PMC free article] [PubMed]
  • Lassus A, Forsström S. A double-blind parallel study comparing sulconazole with econazole in the treatment of dermatophytoses. Mykosen. 1984 Dec;27(12):592–598. [PubMed]
  • Lassus A, Forström S, Salo O. A double-blind comparison of sulconazole nitrate 1% cream with clotrimazole 1% cream in the treatment of dermatophytoses. Br J Dermatol. 1983 Feb;108(2):195–198. [PubMed]
  • Latrille F, Perraud J, Stadler J, Monro AM, Sutter BC. Effects of tioconazole on parturition and serum levels of 17 beta-oestradiol, progesterone, LH and PRL in the rat. Biochem Pharmacol. 1987 Apr 1;36(7):1119–1124. [PubMed]
  • Cornelis G, Laroche Y, Balligand G, Sory MP, Wauters G. Yersinia enterocolitica, a primary model for bacterial invasiveness. Rev Infect Dis. 1987 Jan-Feb;9(1):64–87. [PubMed]
  • Lavrijsen K, Van Houdt J, Thijs D, Meuldermans W, Heykants J. Induction potential of antifungals containing an imidazole or triazole moiety. Miconazole and ketoconazole, but not itraconazole are able to induce hepatic drug metabolizing enzymes of male rats at high doses. Biochem Pharmacol. 1986 Jun 1;35(11):1867–1878. [PubMed]
  • Lefler E, Brummer E, McEwen JG, Hoyos GL, Restrepo A, Stevens DA. Study of current and new drugs in a murine model of acute paracoccidioidomycosis. Am J Trop Med Hyg. 1985 Jan;34(1):134–140. [PubMed]
  • Lefler E, Brummer E, Perlman AM, Stevens DA. Activities of the modified polyene N-D-ornithyl amphotericin methyl ester and the azoles ICI 153066, Bay n 7133, and Bay l 9139 compared with those of amphotericin B and ketoconazole in the therapy of experimental blastomycosis. Antimicrob Agents Chemother. 1985 Mar;27(3):363–366. [PMC free article] [PubMed]
  • Lefler E, Stevens DA. Inhibition and killing of Candida albicans in vitro by five imidazoles in clinical use. Antimicrob Agents Chemother. 1984 Apr;25(4):450–454. [PMC free article] [PubMed]
  • Lefler E, Stevens DA. New azole compounds: vibunazole (Bay n7133) and Bay L9139, compared with ketoconazole in the therapy of systemic candidosis and in pharmacokinetic studies, in mice. J Antimicrob Chemother. 1985 Jan;15(1):69–75. [PubMed]
  • Levine HB. R34000, a dioxolane imidazole in the therapy for experimental coccidioidomycosis. Comparison with miconazole and econazole. Chest. 1976 Dec;70(6):755–759. [PubMed]
  • Levine HB. A direct comparison of oral treatments with BAY-n-7133, BAY-1-9139 and ketoconazole in experimental murine coccidioidomycosis. Sabouraudia. 1984;22(1):37–46. [PubMed]
  • Levine HB, Stevens DA, Cobb JM, Gebhardt AE. Miconazole in coccidioidomycosis. I. Assays of activity in mice and in vitro. J Infect Dis. 1975 Oct;132(4):407–414. [PubMed]
  • Lewis JH, Zimmerman HJ, Benson GD, Ishak KG. Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology. 1984 Mar;86(3):503–513. [PubMed]
  • Loose DS, Kan PB, Hirst MA, Marcus RA, Feldman D. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest. 1983 May;71(5):1495–1499. [PMC free article] [PubMed]
  • Lutwick LI, Rytel MW, Yañez JP, Galgiani JN, Stevens DA. Deep infections from Petriellidium boydii treated with miconazole. JAMA. 1979 Jan 19;241(3):272–273. [PubMed]
  • Lyman CA, Sugar AM, Diamond RD. Comparative activities of UK-49,858 and amphotericin B against Blastomyces dermatitidis infections in mice. Antimicrob Agents Chemother. 1986 Jan;29(1):161–162. [PMC free article] [PubMed]
  • Marcano C, Feo M. Eficacia del econazol en embarazadas con candidiasis vulvo-vaginal. Mycopathologia. 1983 Feb 17;81(2):65–70. [PubMed]
  • Marriott MS, Baird JR, Brammer KW, Faulkner JK, Halliwell G, Jevons S, Tarbit MH. Tioconazole, a new imidazole-antifungal agent for the treatment of dermatomycoses. Antifungal and pharmacologic properties. Dermatologica. 1983;166 (Suppl 1):1–7. [PubMed]
  • Mazabrey D, Nadal J, Seguela JP, Linas MD. Scanning and transmission electron microscopy: study of effects of econazole on Microsporum canis. Mycopathologia. 1985 Sep;91(3):151–157. [PubMed]
  • Meunier-Carpentier F, Cruciani M, Klastersky J. Oral prophylaxis with miconazole or ketoconazole of invasive fungal disease in neutropenic cancer patients. Eur J Cancer Clin Oncol. 1983 Jan;19(1):43–48. [PubMed]
  • Mixich G, Thiele K. Ein Beitrag zur stereospezifischen Synthese von antimykotisch wirksamen Imidazolyloximäthern. Oxiconazol-nitrat (Sgd 301-76), ein neues Breitbandantimykotikum. Arzneimittelforschung. 1979;29(10):1510–1513. [PubMed]
  • Mobacken H, Moberg S. Ketoconazole treatment of 13 patients with chronic mucocutaneous candidiasis. A prospective 3-year trial. Dermatologica. 1986;173(5):229–236. [PubMed]
  • Morita T, Nozawa Y. Effects of antifungal agents on ergosterol biosynthesis in Candida albicans and Trichophyton mentagrophytes: differential inhibitory sites of naphthiomate and miconazole. J Invest Dermatol. 1985 Nov;85(5):434–437. [PubMed]
  • Mosse M, Alric MP, Berceaux M, Fourcine N, Salhi A. Etude comparative de l'activité fongistatique in vitro de l'omoconazole et de six autres imidazolés sur les levures. Pathol Biol (Paris) 1986 Jun;34(5 Pt 2):684–687. [PubMed]
  • Odds FC. Laboratory evaluation of antifungal agents: a comparative study of five imidazole derivatives of clinical importance. J Antimicrob Chemother. 1980 Nov;6(6):749–761. [PubMed]
  • Odds FC, Abbott AB, Pye G, Troke PF. Improved method for estimation of azole antifungal inhibitory concentrations against Candida species, based on azole/antibiotic interactions. J Med Vet Mycol. 1986 Aug;24(4):305–311. [PubMed]
  • Odds FC, Cheesman SL, Abbott AB. Suppression of ATP in Candida albicans by imidazole and derivative antifungal agents. Sabouraudia. 1985 Dec;23(6):415–424. [PubMed]
  • Odds FC, Cheesman SL, Abbott AB. Antifungal effects of fluconazole (UK 49858), a new triazole antifungal, in vitro. J Antimicrob Chemother. 1986 Oct;18(4):473–478. [PubMed]
  • Odds FC, Cockayne A, Hayward J, Abbott AB. Effects of imidazole- and triazole-derivative antifungal compounds on the growth and morphological development of Candida albicans hyphae. J Gen Microbiol. 1985 Oct;131(10):2581–2589. [PubMed]
  • Odds FC, MacDonald F. Persistence of miconazole in vaginal secretions after single applications. Implications for the treatment of vaginal candidosis. Br J Vener Dis. 1981 Dec;57(6):400–401. [PMC free article] [PubMed]
  • Odds FC, Milne LJ, Gentles JC, Ball EH. The activity in vitro and in vivo of a new imidazole antifungal, ketoconazole. J Antimicrob Chemother. 1980 Jan;6(1):97–104. [PubMed]
  • Odds FC, Webster CE, Abbott AB. Antifungal relative inhibition factors: BAY l-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole and vibunazole (BAY n-7133) compared in vitro with nine established antifungal agents. J Antimicrob Chemother. 1984 Aug;14(2):105–114. [PubMed]
  • Ogata M, Matsumoto H, Hamada Y, Takehara M, Tawara K. 1-[1-[2-[(3-Chlorobenzyl)oxy]phenyl]vinyl]-1H-imidazole hydrochloride, a new potent antifungal agent. J Med Chem. 1983 May;26(5):768–770. [PubMed]
  • Oji EO, Clayton YM. The role of econazole in the management of oculomycosis. Int Ophthalmol. 1982 Feb;4(3):137–142. [PubMed]
  • O'Neill East M, Henderson JT, Jevons S. Tioconazole in the treatment of fungal infections of the skin. An international clinical research program. Dermatologica. 1983;166 (Suppl 1):20–33. [PubMed]
  • Osumi M, Yamada N, Okada J, Yamaguchi H, Hiratani T, Plempel M. The effect of bifonazole on the structure of Trichophyton. Arzneimittelforschung. 1983;33(10):1484–1491. [PubMed]
  • Palou de Fernandez E, Patino MM, Graybill JR, Tarbit MH. Treatment of cryptococcal meningitis in mice with fluconazole. J Antimicrob Chemother. 1986 Aug;18(2):261–270. [PubMed]
  • Perfect JR, Durack DT. Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. J Antimicrob Chemother. 1985 Jul;16(1):81–86. [PubMed]
  • Perfect JR, Savani DV, Durack DT. Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. Antimicrob Agents Chemother. 1986 Apr;29(4):579–583. [PMC free article] [PubMed]
  • Plempel M. On the action kinetics of clotrimazole. Chemotherapy. 1982;28 (Suppl 1):22–31. [PubMed]
  • Plempel M. Antimycotic activity of BAY N 7133 in animal experiments. J Antimicrob Chemother. 1984 May;13(5):447–463. [PubMed]
  • Plempel M, Bartmann K, Büchel KH, Regel E. Experimentelle Befunde über ein neues, oral wirksames Antimykotikum mit breiten Wirkungsspektrum. Dtsch Med Wochenschr. 1969 Jun 27;94(26):1356–passim. [PubMed]
  • Plempel M, Regel E, Büchel KH. Antimycotic efficacy of bifonazole in vitro and in vivo. Arzneimittelforschung. 1983;33(4):517–524. [PubMed]
  • Polak A. Oxiconazole, a new imidazole derivative. Evaluation of antifungal activity in vitro and in vivo. Arzneimittelforschung. 1982;32(1):17–24. [PubMed]
  • Polak A. Antifungal activity of four antifungal drugs in the cutaneous retention time test. Sabouraudia. 1984;22(6):501–503. [PubMed]
  • Polak A, Dixon DM. Fungistatic and fungicidal effects of amphotericin B, ketoconazole and fluconazole (UK 49,858) against histoplasma capsulatum in vitro and in vivo. Mykosen. 1987 Apr;30(4):186–194. [PubMed]
  • Polak A, Scholer HJ, Wall M. Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice. Chemotherapy. 1982;28(6):461–479. [PubMed]
  • Polak-Wyss A, Lengsfeld H, Oesterhelt G. Effect of oxiconazole and Ro 14-4767/002 on sterol pattern in Candida albicans. Sabouraudia. 1985 Dec;23(6):433–441. [PubMed]
  • Pont A, Williams PL, Loose DS, Feldman D, Reitz RE, Bochra C, Stevens DA. Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med. 1982 Sep;97(3):370–372. [PubMed]
  • Preusser HJ, Rostek H. Econazole effects on Trichophyton rubrum and Candida albicans--electron microscopic and cytochemical studies. Mykosen Suppl. 1978;1:314–321. [PubMed]
  • Pye GW, Marriott MS. Inhibition of sterol C14 demethylation by imidazole-containing antifungals. Sabouraudia. 1982 Dec;20(4):325–329. [PubMed]
  • Rajfer J, Sikka SC, Rivera F, Handelsman DJ. Mechanism of inhibition of human testicular steroidogenesis by oral ketoconazole. J Clin Endocrinol Metab. 1986 Nov;63(5):1193–1198. [PubMed]
  • Reingold AL, Lu XD, Plikaytis BD, Ajello L. Systemic mycoses in the United States, 1980-1982. J Med Vet Mycol. 1986 Dec;24(6):433–436. [PubMed]
  • States B, Palmieri MJ, Segal S. Uptake of proline in cultured cells from patients with Lowe's syndrome. Biochem Biophys Res Commun. 1982 Nov 30;109(2):428–433. [PubMed]
  • Richardson K, Brammer KW, Marriott MS, Troke PF. Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes. Antimicrob Agents Chemother. 1985 May;27(5):832–835. [PMC free article] [PubMed]
  • Ritter W, Plempel M. Pharmacokinetics of the oral triazole antimycotic vibunazole in animals. J Antimicrob Chemother. 1984 Sep;14(3):243–252. [PubMed]
  • Roberts DT, Adriaans B, Gentles JC. A comparative study of once daily bifonazole cream versus twice daily miconazole cream in the treatment of tinea pedis. Mykosen. 1985 Nov;28(11):550–552. [PubMed]
  • ROBINSON HJ, PHARES HF, GRAESSLE OE. ANTIMYCOTIC PROPERTIES OF THIABENDAZOLE. J Invest Dermatol. 1964 Jun;42:479–482. [PubMed]
  • Rogers TE, Galgiani JN. Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother. 1986 Sep;30(3):418–422. [PMC free article] [PubMed]
  • Rohde-Werner H. Topical tioconazole versus systemic ketoconazole treatment of vaginal candidiasis. J Int Med Res. 1984;12(5):298–302. [PubMed]
  • Rohwedder JJ, Archer G. Pulmonary sporotrichosis: Treatment with miconazole. Am Rev Respir Dis. 1976 Aug;114(2):403–406. [PubMed]
  • Rumler W, Heins S. Konzentrations-Kontaktzeit-Beziehungen bei der Wirkung von Clotrimazol auf Candida albicans. Mykosen. 1983 Jun;26(6):293–297. [PubMed]
  • Rumler W, Heins S, Heins J. Beziehungen zwischen Antimykotikum-Konzentration und Kontaktzeit bei der Wirkung von 5-Fluorzytosin, Bifonazol und BAY N 7133 auf Candida albicans. Mykosen. 1984 Sep;27(9):436–442. [PubMed]
  • Rutgeerts L, Verhaegen H. Intravenous miconazole in the treatment of chronic esophageal candidiasis. Gastroenterology. 1977 Feb;72(2):316–318. [PubMed]
  • Ryley JF, Wilson RG, Barrett-Bee KJ. Azole resistance in Candida albicans. Sabouraudia. 1984;22(1):53–63. [PubMed]
  • Santen RJ, Van den Bossche H, Symoens J, Brugmans J, DeCoster R. Site of action of low dose ketoconazole on androgen biosynthesis in men. J Clin Endocrinol Metab. 1983 Oct;57(4):732–736. [PubMed]
  • Savani DV, Perfect JR, Cobo LM, Durack DT. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother. 1987 Jan;31(1):6–10. [PMC free article] [PubMed]
  • Schaffner A, Frick PG. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. J Infect Dis. 1985 May;151(5):902–910. [PubMed]
  • Schär G, Kayser FH, Dupont MC. Antimicrobial activity of econazole and miconazole in vitro and in experimental candidiasis and aspergillosis. Chemotherapy. 1976;22(3-4):211–220. [PubMed]
  • Schürmeyer T, Nieschlag E. Effect of ketoconazole and other imidazole fungicides on testosterone biosynthesis. Acta Endocrinol (Copenh) 1984 Feb;105(2):275–280. [PubMed]
  • Scott EM, Gorman SP, McGrath SJ. Inhibition of hyphal development in Trichophyton mentagrophytes arthroconidia by ketoconazole and miconazole. J Antimicrob Chemother. 1985 Apr;15(4):405–415. [PubMed]
  • Scott EM, Gorman SP, Millership JS, Wright LR. Effect of miconazole and clotrimazole on K+ release and inhibition of ergosterol biosynthesis in Trichophyton mentagrophytes and related ultrastructural observations. J Antimicrob Chemother. 1986 Apr;17(4):423–432. [PubMed]
  • Shadomy S. In vitro antifungal activity of clotrimazole (Bay b 5097). Infect Immun. 1971 Aug;4(2):143–148. [PMC free article] [PubMed]
  • Shadomy S, Dixon DM, May R. A comparison of bifonazole (BAY H 4502) with clotrimazole in vitro. Sabouraudia. 1982 Dec;20(4):313–323. [PubMed]
  • Shadomy S, Espinel-Ingroff A, Kerkering TM. In-vitro studies with four new antifungal agents: BAY n 7133, bifonazole (BAY h 4502), ICI 153,066 and Ro 14-4767/002. Sabouraudia. 1984;22(1):7–15. [PubMed]
  • Shadomy S, Espinel-Ingroff A, Tartaglione TA, Dismukes WE. Treatment of systemic mycoses with ketoconazole: studies of ketoconazole serum levels. Mykosen. 1986 May;29(5):195–209. [PubMed]
  • Shadomy S, White SC, Yu HP, Dismukes WE. Treatment of systemic mycoses with ketoconazole: in vitro susceptibilities of clinical isolates of systemic and pathogenic fungi to ketoconazole. J Infect Dis. 1985 Dec;152(6):1249–1256. [PubMed]
  • Shepp DH, Klosterman A, Siegel MS, Meyers JD. Comparative trial of ketoconazole and nystatin for prevention of fungal infection in neutropenic patients treated in a protective environment. J Infect Dis. 1985 Dec;152(6):1257–1263. [PubMed]
  • Shigematsu ML, Uno J, Arai T. Effect of ketoconazole on isolated mitochondria from Candida albicans. Antimicrob Agents Chemother. 1982 Jun;21(6):919–924. [PMC free article] [PubMed]
  • Slotman GJ, Burchard KW. Ketoconazole prevents Candida sepsis in critically ill surgical patients. Arch Surg. 1987 Feb;122(2):147–151. [PubMed]
  • Sobel JD. Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. N Engl J Med. 1986 Dec 4;315(23):1455–1458. [PubMed]
  • Sobel JD, Muller G. Comparison of ketoconazole, Bay N7133, and Bay L9139 in the treatment of experimental vaginal candidiasis. Antimicrob Agents Chemother. 1983 Sep;24(3):434–436. [PMC free article] [PubMed]
  • Sobel JD, Muller G. Comparison of itraconazole and ketoconazole in the treatment of experimental candidal vaginitis. Antimicrob Agents Chemother. 1984 Aug;26(2):266–267. [PMC free article] [PubMed]
  • Sonino N. The endocrine effects of ketoconazole. J Endocrinol Invest. 1986 Aug;9(4):341–347. [PubMed]
  • Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med. 1987 Sep 24;317(13):812–818. [PubMed]
  • Stenderup A, Schønheyder H. Mycoses complicating AIDS. Microbiol Sci. 1984 Dec;1(9):219–223. [PubMed]
  • Stevens D. Miconazole in the treatment of systemic fungal infections. Am Rev Respir Dis. 1977 Nov;116(5):801–806. [PubMed]
  • Stevens DA. Miconazole in the treatment of coccidioidomycosis. Drugs. 1983 Oct;26(4):347–354. [PubMed]
  • Stevens DA, Levine HB, Deresinski SC. Miconazole in coccidiodomycosis. II. Therapeutic and pharmacologic studies in man. Am J Med. 1976 Feb;60(2):191–202. [PubMed]
  • Stüttgen G, Bauer E. Bioavailability, skin- and nailpenetration of topically applied antimycotics. Mykosen. 1982 Feb;25(2):74–80. [PubMed]
  • Stüttgen G, Bauer E. Permeation von markiertem Oxiconazol. Vergleich der autoradiographischen mit der Horizontalschnitt-Technik an menschlicher Haut. Mykosen. 1985 Mar;28(3):138–147. [PubMed]
  • Sud IJ, Feingold DS. Heterogeneity of action of mechanisms among antimycotic imidazoles. Antimicrob Agents Chemother. 1981 Jul;20(1):71–74. [PMC free article] [PubMed]
  • Sud IJ, Feingold DS. Mechanisms of action of the antimycotic imidazoles. J Invest Dermatol. 1981 Jun;76(6):438–441. [PubMed]
  • Sung JP, Grendahl JG, Levine HB. Intravenous and intrathecal miconazole therapy for systemic mycoses. West J Med. 1977 Jan;126(1):5–13. [PMC free article] [PubMed]
  • Tanenbaum L, Anderson C, Rosenberg MJ, Akers W. 1% sulconazole cream v 2% miconazole cream in the treatment of tinea versicolor. A double-blind, multicenter study. Arch Dermatol. 1984 Feb;120(2):216–219. [PubMed]
  • Tanenbaum L, Anderson C, Rosenberg MJ, Howard W, McDaniel W, Neimanis A, Ryan ME, Perez R. Sulconazole nitrate 1.0 percent cream: a comparison with miconazole in the treatment of tinea pedis and tinea cruris/corporis. Cutis. 1982 Jul;30(1):105–118. [PubMed]
  • Täuber U. Availability of isoconazole in human skin after dermal application as free base and as nitrate in vitro. Arzneimittelforschung. 1987 Apr;37(4):461–463. [PubMed]
  • Täuber U, Rach P, Lachnit U. Persistence of isoconazole in vaginal secretion after single application. Mykosen. 1984 Feb;27(2):97–101. [PubMed]
  • Taylor FR, Rodriguez RJ, Parks LW. Relationship between antifungal activity and inhibition of sterol biosynthesis in miconazole, clotrimazole, and 15-azasterol. Antimicrob Agents Chemother. 1983 Apr;23(4):515–521. [PMC free article] [PubMed]
  • Thienpont D, Van Cutsem J, Van Gerven F, Heeres J, Janssen PA. Ketoconazole -- a new broad spectrum orally active antimycotic. Experientia. 1979 May 15;35(5):606–607. [PubMed]
  • Thienpont D, Van Cutsem J, Van Nueten JM, Niemegeers CJ, Marsboom R. Bilogical and toxicological properties of econazole, a broad-spectrum antimycotic. Arzneimittelforschung. 1975 Feb;25(2):224–230. [PubMed]
  • Tolman EL, Isaacson DM, Rosenthale ME, McGuire JL, Van Cutsem J, Borgers M, Van den Bossche H. Anticandidal activities of terconazole, a broad-spectrum antimycotic. Antimicrob Agents Chemother. 1986 Jun;29(6):986–991. [PMC free article] [PubMed]
  • Trachtenberg J. Ketoconazole therapy in advanced prostatic cancer. J Urol. 1984 Jul;132(1):61–63. [PubMed]
  • Troke PF, Andrews RJ, Brammer KW, Marriott MS, Richardson K. Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice. Antimicrob Agents Chemother. 1985 Dec;28(6):815–818. [PMC free article] [PubMed]
  • Troke PF, Andrews RJ, Marriott MS, Richardson K. Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice. J Antimicrob Chemother. 1987 May;19(5):663–670. [PubMed]
  • Ueda AK, Franco M, Fabio SA, Prestes FR. Ketoconazole in the treatment of experimental murine paracoccidioidomycosis. Mycopathologia. 1987 Apr;98(1):27–34. [PubMed]
  • Uno J, Shigematsu ML, Arai T. Primary site of action of ketoconazole on Candida albicans. Antimicrob Agents Chemother. 1982 Jun;21(6):912–918. [PMC free article] [PubMed]
  • Utz JP. Chemotherapy for the systemic mycoses: the prelude to ketoconazole. Rev Infect Dis. 1980 Jul-Aug;2(4):625–632. [PubMed]
  • Van Cutsem J. The antifungal activity of ketoconazole. Am J Med. 1983 Jan 24;74(1B):9–15. [PubMed]
  • Van Cutsem J, Fransen J, Janssen PA. Therapeutic efficacy of itraconazole in systemic candidosis in guinea pigs. Chemotherapy. 1987;33(1):52–60. [PubMed]
  • Van Cutsem J, Fransen J, Van Gerven F, Janssen PA. Oral treatment with ketoconazole in systemic candidosis of guinea-pigs: microbiology, hematology and histopathology. Sabouraudia. 1985 Jun;23(3):189–198. [PubMed]
  • Van Cutsem J, Van Gerven F, Van de Ven MA, Borgers M, Janssen PA. Itraconazole, a new triazole that is orally active in aspergillosis. Antimicrob Agents Chemother. 1984 Oct;26(4):527–534. [PMC free article] [PubMed]
  • Van Cutsem J, Van Gerven F, Zaman R, Janssen PA. Terconazole - a new broad-spectrum antifungal. Chemotherapy. 1983;29(5):322–331. [PubMed]
  • Van Cutsem JM, Thienpont D. Miconazole, a broad-spectrum antimycotic agent with antibacterial activity. Chemotherapy. 1972;17(6):392–404. [PubMed]
  • Van den Bossche H. Biochemical effects of miconazole on fungi. I. Effects on the uptake and or utilization of purines, pyrimidines, nucleosides, amino acids and glucose by Candida albicans. Biochem Pharmacol. 1974 Feb 15;23(4):887–899. [PubMed]
  • Vanden Bossche H. Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action. Curr Top Med Mycol. 1985;1:313–351. [PubMed]
  • van Gulpen C, Kelder O, Mattie H, van der Meer JW, van't Wout J. Pharmacokinetics of vibunazole (BAY n 7133) administered orally to healthy subjects. J Antimicrob Chemother. 1985 Jul;16(1):75–79. [PubMed]
  • van Rensburg CE, Anderson R, Jooné G, van der Merwe MF, Eftychis HA. The effects of ketoconazole on cellular and humoral immune functions. J Antimicrob Chemother. 1983 Jan;11(1):49–55. [PubMed]
  • Veronese M, Barzaghi D, Bertoncini A. Antifungal activity of fenticonazole in experimental dermatomycosis and candidiasis. Arzneimittelforschung. 1981;31(12):2137–2139. [PubMed]
  • Veronese M, Salvaterra M, Barzaghi D. Fenticonazole, a new imidazole derivative with antibacterial and antifungal activity. In vitro study. Arzneimittelforschung. 1981;31(12):2133–2137. [PubMed]
  • Wade TR, Jones HE, Chanda JJ. Intravenous miconazole therapy of mycotic infections. Arch Intern Med. 1979 Jul;139(7):784–786. [PubMed]
  • Wagner W. Vergleich der klinischen Wirksamkeit und Verträglichkeit von Oxiconazol nach 1 x täglicher Applikation mit der nach 2 x täglicher Applikation. Mykosen. 1986 Jun;29(6):280–284. [PubMed]
  • Walker KA, Braemer AC, Hitt S, Jones RE, Matthews TR. 1-[4-(4-Chlorophenyl)-2-(2,6-dichlorophenylthio)-n-butyl]-1H-imidazole nitrate, a new potent antifungal agent. J Med Chem. 1978 Aug;21(8):840–843. [PubMed]
  • Walther M. Feldstudie Die Einmaltherapie von Vaginalmykosen mit isoconazolnitrat. Schweiz Rundsch Med Prax. 1982 Jan 26;71(4):152–156. [PubMed]
  • Weisberg M. Treatment of vaginal candidiasis in pregnant women. Clin Ther. 1986;8(5):563–567. [PubMed]
  • Wishart JM, Gould PW. Econazole treatment of fungal infections: an open trial. N Z Med J. 1981 Sep 23;94(692):226–227. [PubMed]
  • Woestenborghs R, Lorreyne W, Heykants J. Determination of itraconazole in plasma and animal tissues by high-performance liquid chromatography. J Chromatogr. 1987 Jan 23;413:332–337. [PubMed]
  • Wood PR, Tarbit MH. Gas chromatographic method for the determination of fluconazole, a novel antifungal agent, in human plasma and urine. J Chromatogr. 1986 Nov 28;383(1):179–186. [PubMed]
  • Yamaguchi H, Hiratani T, Plempel M. In vitro studies of a new imidazole antimycotic, bifonazole, in comparison with clotrimazole and miconazole. Arzneimittelforschung. 1983;33(4):546–551. [PubMed]
  • Yamaguchi H, Hiratani T, Plempel M. In-vitro studies of a new oral azole antimycotic, BAY N 7133. J Antimicrob Chemother. 1983 Feb;11(2):135–149. [PubMed]
  • Yamaguchi H, Iwata K. Effect of two imidazole antimycotics, clotrimazole and miconazole on amino acid transport in Candida albicans. Sabouraudia. 1979 Sep;17(3):311–322. [PubMed]
  • Yap BS, Bodey GP. Oropharyngeal candidiasis treated with a troche form of clotrimazole. Arch Intern Med. 1979 Jun;139(6):656–657. [PubMed]
  • Yozwiak ML, Galgiani JN. Itraconazole treatment of experimental systemic candidiasis in male rats. J Med Vet Mycol. 1987 Apr;25(2):125–126. [PubMed]

Articles from Clinical Microbiology Reviews are provided here courtesy of American Society for Microbiology (ASM)